GRI Bio (GRI) Competitors $1.66 +0.16 (+10.67%) As of 09/5/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. NXTC, SNGX, TXMD, LGVN, HCWB, BFRG, IMCC, MRKR, LPTX, and MBRXShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include NextCure (NXTC), Soligenix (SNGX), TherapeuticsMD (TXMD), Longeveron (LGVN), HCW Biologics (HCWB), Bullfrog AI (BFRG), IM Cannabis (IMCC), Marker Therapeutics (MRKR), Leap Therapeutics (LPTX), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors NextCure Soligenix TherapeuticsMD Longeveron HCW Biologics Bullfrog AI IM Cannabis Marker Therapeutics Leap Therapeutics Moleculin Biotech NextCure (NASDAQ:NXTC) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations. Which has preferable earnings & valuation, NXTC or GRI? NextCure is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$55.65M-$25.82-0.19GRI BioN/AN/A-$8.21M-$11.56-0.14 Is NXTC or GRI more profitable? NextCure's return on equity of -106.62% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -106.62% -85.20% GRI Bio N/A -327.62%-191.40% Do analysts rate NXTC or GRI? NextCure presently has a consensus price target of $25.50, indicating a potential upside of 418.82%. GRI Bio has a consensus price target of $22.00, indicating a potential upside of 1,225.30%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in NXTC or GRI? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 17.9% of NextCure shares are owned by company insiders. Comparatively, 0.9% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, NXTC or GRI? NextCure has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.59, indicating that its stock price is 259% less volatile than the S&P 500. Does the media favor NXTC or GRI? In the previous week, GRI Bio had 1 more articles in the media than NextCure. MarketBeat recorded 3 mentions for GRI Bio and 2 mentions for NextCure. GRI Bio's average media sentiment score of 0.99 beat NextCure's score of 0.50 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NextCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGRI Bio beats NextCure on 7 of the 12 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.18M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E Ratio-0.1421.1076.1526.11Price / SalesN/A466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book0.229.8711.486.09Net Income-$8.21M-$53.42M$3.29B$266.51M7 Day Performance19.42%2.93%1.27%0.46%1 Month Performance32.80%9.85%7.94%4.59%1 Year Performance-80.95%15.74%62.94%26.04% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio3.1974 of 5 stars$1.66+10.7%$22.00+1,225.3%-80.1%$4.18MN/A-0.141News CoverageShort Interest ↓High Trading VolumeNXTCNextCure4.601 of 5 stars$5.03-1.9%$25.50+407.0%-71.6%$13.46MN/A-0.1990News CoveragePositive NewsShort Interest ↓SNGXSoligenix2.5051 of 5 stars$3.10+1.3%$6.00+93.5%-31.1%$13.28M$120K-0.8220Positive NewsShort Interest ↓TXMDTherapeuticsMD0.2218 of 5 stars$1.11-0.9%N/A-39.3%$12.85M$1.76M0.00420LGVNLongeveron2.2668 of 5 stars$0.83-0.2%$7.67+825.8%-63.3%$12.57M$2.39M-0.1320Short Interest ↑HCWBHCW Biologics3.1249 of 5 stars$5.72+0.7%$35.00+511.9%-81.1%$12.31M$2.57M-0.4140Positive NewsShort Interest ↓BFRGBullfrog AI0.7051 of 5 stars$1.21-1.6%N/A-54.2%$12.20M$60K-1.594IMCCIM Cannabis0.235 of 5 stars$2.32-4.9%N/A-11.7%$12.17M$39.44M-4.30340News CoverageShort Interest ↑Gap DownMRKRMarker Therapeutics4.207 of 5 stars$0.93+3.3%$13.17+1,322.3%-71.3%$11.98M$6.59M-0.6860Positive NewsShort Interest ↓LPTXLeap Therapeutics1.5018 of 5 stars$0.29-2.3%$3.38+1,070.2%-90.3%$11.95MN/A-0.1840MBRXMoleculin Biotech3.1683 of 5 stars$0.39-0.2%$4.00+919.4%-84.9%$11.88MN/A0.0020Analyst RevisionGap Down Related Companies and Tools Related Companies NXTC Alternatives SNGX Alternatives TXMD Alternatives LGVN Alternatives HCWB Alternatives BFRG Alternatives IMCC Alternatives MRKR Alternatives LPTX Alternatives MBRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
